Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-11-29
2005-11-29
Lacourcire, Karen A. (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S024300, C536S024330, C536S024500
Reexamination Certificate
active
06969704
ABSTRACT:
The invention provides a method for reducing damage to an ischemic tissue which comprises contacting cells of the tissue with an inhibitor of Early Growth Response Factor-1 Protein (Egr-1). In addition, the invention provides a method for reducing vascular injury during reperfusion of an ischemic tissue in a subject which comprises contacting the tissue with a compound which inhibits expression of Early Growth Response Factor-1 (Egr-1) protein in the tissue so as to reduce vascular injury in the tissue during reperfusion. wherein the inhibitor is a nucleic acid consisting essentially of the polynucleotide sequence 5′-CTTGGCCGCTGCCAT-3′ (SEQ ID NO:1). In one embodiment of the invention, the subject has suffered a stroke, or a myocardial infarction. In another embodiment of the invention, the subject is undergoing or has undergone angioplasty, cardiac surgery, vascular surgery, or organ transplantation.
REFERENCES:
patent: 5593974 (1997-01-01), Rosenberg et al.
Gewirtz et al. Facilitating oligonucleotide delivery: Helping antisense deliver on its promise. Proc. Natl. Acad. Sci, 1996 vol. 93:3161-3163).
SL Lee et al., Science, Luteinizing Hormone Deficiency and Female Infertility in Mice Lacking the Transcription Factor NGGI-A (Egr-1) Aug. 1996, vol. 273, pp. 1219-1221.
P Topilko et al., Molecular Endocrinology, “Multiple Pituitary and Ovarian Defects in Krox-24 (NGFI-A, Egr-1)-Targeted Mice,” 1998, 12: pp. 107-122.
E Murphy et al., Circulation Research, “Sodium Regulation During Ischemia Versus Reperfusion and its Role in Injury,” 1999, 84:1469-1470.
DR Meldrum, Journal of Surgical Research, “Mechanims of Cardiac Preconditioning: Ten Years after the Discovery of Ischemic Preconditioning,” 1997, 73, pp. 1-13.
H Yoshidome et al., Journal of Surgicla Research, “Enhanced Pulmonary Expression of CXC Chemokines during Hepatic Ischemia/Reperfusion-Induced Lung Injury in Mice,” 1999, 81, pp. 33-37.
FS Santiago et al., American Journal of Pathology, “Vasular Smooth Muscle Cell Proliferation and Regrowth after Mechanical Injury in Vitro Are Egr-1/NGFI-A-Dependent,” Sep. 1999, vol. 155, No. 3, pp. 897-905.
K-Y Jen et al., Stem Cells, “Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies,” 2000, 18: 307-319.
AD Branch, TIBS, “A good antisense molecule is hard to find,” Feb. 1998, pp. 45-50.
Gashler, A. & Sukhatme, V. Egr-1: prototype of a zinc finger fan-lily of transcription factors. Prog. Nucl. Acids Res. and Molec. Biol. 50, 191-224 (1995).
Nguyen, H., Hoffman-Lieberman, B. & Liebennann, D. Egr-1 is essential for and restricts differentiation along the macrophage cell lineage. Cell 72, 197-209 (1993).
Yan, S-F., et al. Tissue factor transcription driven by Egr-1 is a critical mechanism of murine pulmonary fibrin deposition in hypoxia. Proc Natl Acad Sci 95, 8298-8303 (1998).
Okada, K., et al. Potentiation of endogenous fibrinolysis and rescue from lung ischemia-reperfusion injury in IL-10-reconstituted IL-10 null mice. J. Biol. Chem. epub ahead of print (2000).
Lee, S., et al. Early expression of angiogenesis factors in acute myocardial ischemia. New Engl J Med 342, 626-633 (2000).
Liu, P., et al. Role of endogenous nitric oxide in TNF-α and IL-1-1β generation in hepatic ischemia-reperfusion. Shock 13, 217-223 (2000).
Mechtcheriakova, D., et al. VEGF-induced tissue factor expression in endothelial cells is mediated by Egr-1. Blood 93, 3 811-3123 (1999).
Khachigian, L., Lindner, V., Williams, A. & Collins, T. Egr-1-induced endothelial gene expression: a common theme in vascular injury. Science 271, 1427-1431 (1996).
Pinsky David
Stern David M.
Yan Shi-Fang
Cooper & Dunham LLP
Gibbs Terra C.
Lacourcire Karen A.
The Trustees of Columbia University in the City of New York
White, Esq. John P.
LandOfFree
Methods for suppressing early growth... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for suppressing early growth..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for suppressing early growth... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3512944